Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Diabetic osteoarthropathy care in Sweden - Need for improvement: A national inventory.

Wennberg L, Lundgren P, Axelsson R, Aspelin P, Gerok-Andersson K, Åkerlund B.

J Clin Transl Endocrinol. 2017 Jun 29;9:32-37. doi: 10.1016/j.jcte.2017.06.001. eCollection 2017 Sep.

2.

Liraglutide and Renal Outcomes in Type 2 Diabetes.

Mann JFE, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornøe K, Zinman B, Buse JB; LEADER Steering Committee and Investigators.

N Engl J Med. 2017 Aug 31;377(9):839-848. doi: 10.1056/NEJMoa1616011.

3.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators.

N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13.

4.

[Of what value is improved accessibility without good treatment outcome?].

Akerlund B, Gerok-Andersson K, Saro C.

Lakartidningen. 2011 Aug 10-23;108(32-33):1477. Swedish. No abstract available.

PMID:
21922937
5.

Apligraf in the treatment of neuropathic diabetic foot ulcers.

Edmonds M; European and Australian Apligraf Diabetic Foot Ulcer Study Group.

Int J Low Extrem Wounds. 2009 Mar;8(1):11-8. doi: 10.1177/1534734609331597. Epub 2009 Feb 3.

PMID:
19189997
6.

[Treatment outcome as quality indicator more important than accessibility].

Akerlund B, Gerok-Andersson K, Hedlund H.

Lakartidningen. 2008 Jun 11-24;105(24-25):1867-8. Swedish. No abstract available.

PMID:
18619015

Supplemental Content

Loading ...
Support Center